Katherine Berry
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Katherine Berry has a total of 125 co-authors. Here are the top co-authors by number of shared publications:
- Linda Pax Lowes
Nationwide Children's Hospital, Columbus, OH
5 shared publications - Lindsay N. Alfano
Nationwide Children's Hospital, Columbus, OH
5 shared publications - Evan Luther
Department of Neurological Surgery, University of Miami School of Medicine, Miami, Florida, USA
2 shared publications - Jerry R. Mendell
Center for Gene Therapy, Nationwide Children’s Hospital, Columbus, USA
2 shared publications - Kevin M. Flanigan
Center for Gene Therapy, The Abigail Wexner Research Institute at Nationwide Children’s Hospital, Columbus, Ohio, USA
2 shared publications - Martin Andres Merenzon
Department of Neurosurgery, Johns Hopkins School of Medicine, Baltimore, Maryland
2 shared publications
Latest Publications
- 6 April 2024
- Published by Elsevier in World Neurosurgery
- Vol. 186, e440-e448
The Effect of the Coronavirus Disease 2019 Pandemic on Pituitary Surgery
- 6 April 2024
- Published by Elsevier in World Neurosurgery
- Vol. 186, e440-e448
The Effect of the Coronavirus Disease 2019 Pandemic on Pituitary Surgery
- Open Access
- 31 December 2023
- Published by The Korean Spinal Neurosurgery Society in Neurospine
- Vol. 20 (4) , 1399-1406
Effects of Obesity on Cervical Disc Arthroplasty Complications
Objective: High body mass index is a well-established modifiable comorbidity that is known to increase postoperative complications in all types of surgery, including spine surgery. Obesity is increasing in prevalence amongst the general population. As this growing population of obese patients ages, understanding how they faire undergoing cervical disc arthroplasty (CDA) is important for providing safe and effective evidence-based care for cervical degenerative pathology.Methods: Our study used the Healthcare Cost and Utilization Project’s National Inpatient Sample to assess patients undergoing CDA comparing patient characteristics and outcomes in nonobese patients to obese patients from 2004 to 2014.Results: Our study found a significant increase in the overall utilization of CDA as a treatment modality (p = 0.012) and a statistically significant increase in obese patients undergoing CDA (p < 0.0001) from 2004 to 2014. Obesity was identified as an independent risk factor associated with increased rates of inpatient neurologic complications (odds ratio [OR], 6.99; p = 0.03), pulmonary embolus (OR, 5.41; p = 0.05), and wound infection (OR, 6.97; p < 0.001) in patients undergoing CDA from 2004 to 2014.Conclusion: In patients undergoing CDA, from 2004 to 2014, obesity was identified as an independent risk factor with significantly increased rates of inpatient neurologic complications, pulmonary embolus and wound infection. Large prospective trials are needed to validate these findings.
- 31 December 2023
- Published by The Korean Spinal Neurosurgery Society in Neurospine
- Vol. 20 (4) , 1399-1406
Open AccessEffects of Obesity on Cervical Disc Arthroplasty Complications
Objective: High body mass index is a well-established modifiable comorbidity that is known to increase postoperative complications in all types of surgery, including spine surgery. Obesity is increasing in prevalence amongst the general population. As this growing population of obese patients ages, understanding how they faire undergoing cervical disc arthroplasty (CDA) is important for providing safe and effective evidence-based care for cervical degenerative pathology.Methods: Our study used the Healthcare Cost and Utilization Project’s National Inpatient Sample to assess patients undergoing CDA comparing patient characteristics and outcomes in nonobese patients to obese patients from 2004 to 2014.Results: Our study found a significant increase in the overall utilization of CDA as a treatment modality (p = 0.012) and a statistically significant increase in obese patients undergoing CDA (p < 0.0001) from 2004 to 2014. Obesity was identified as an independent risk factor associated with increased rates of inpatient neurologic complications (odds ratio [OR], 6.99; p = 0.03), pulmonary embolus (OR, 5.41; p = 0.05), and wound infection (OR, 6.97; p < 0.001) in patients undergoing CDA from 2004 to 2014.Conclusion: In patients undergoing CDA, from 2004 to 2014, obesity was identified as an independent risk factor with significantly increased rates of inpatient neurologic complications, pulmonary embolus and wound infection. Large prospective trials are needed to validate these findings.
- 11 February 2023
- Published by Elsevier in World Neurosurgery
- Vol. 173, e91-e108
Surgically Treated Brain Metastases from Uterine Origin: A Case Series and Systematic Review
- 11 February 2023
- Published by Elsevier in World Neurosurgery
- Vol. 173, e91-e108
Surgically Treated Brain Metastases from Uterine Origin: A Case Series and Systematic Review
- 1 February 2021
- Published by Elsevier in World Neurosurgery
- Vol. 146, e1-e5
The Effects of Lockdown During the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Pandemic on Neurotrauma-Related Hospital Admissions
- 1 February 2021
- Published by Elsevier in World Neurosurgery
- Vol. 146, e1-e5
The Effects of Lockdown During the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Pandemic on Neurotrauma-Related Hospital Admissions
- Open Access
- 29 January 2019
- Published by Wolters Kluwer Health in Neurology
- Vol. 92 (5) , e461-e474
Assessment of disease progression in dysferlinopathy
Objective To assess the ability of functional measures to detect disease progression in dysferlinopathy over 6 months and 1 year. Methods One hundred ninety-three patients with dysferlinopathy were recruited to the Jain Foundation9s International Clinical Outcome Study for Dysferlinopathy. Baseline, 6-month, and 1-year assessments included adapted North Star Ambulatory Assessment (a-NSAA), Motor Function Measure (MFM-20), timed function tests, 6-minute walk test (6MWT), Brooke scale, Jebsen test, manual muscle testing, and hand-held dynamometry. Patients also completed the ACTIVLIM questionnaire. Change in each measure over 6 months and 1 year was calculated and compared between disease severity (ambulant [mild, moderate, or severe based on a-NSAA score] or nonambulant [unable to complete a 10-meter walk]) and clinical diagnosis. Results The functional a-NSAA test was the most sensitive to deterioration for ambulant patients overall. The a-NSAA score was the most sensitive test in the mild and moderate groups, while the 6MWT was most sensitive in the severe group. The 10-meter walk test was the only test showing significant change across all ambulant severity groups. In nonambulant patients, the MFM domain 3, wrist flexion strength, and pinch grip were most sensitive. Progression rates did not differ by clinical diagnosis. Power calculations determined that 46 moderately affected patients are required to determine clinical effectiveness for a hypothetical 1-year clinical trial based on the a-NSAA as a clinical endpoint. Conclusion Certain functional outcome measures can detect changes over 6 months and 1 year in dysferlinopathy and potentially be useful in monitoring progression in clinical trials. ClinicalTrials.gov identifier: NCT01676077.
- 29 January 2019
- Published by Wolters Kluwer Health in Neurology
- Vol. 92 (5) , e461-e474
Open AccessAssessment of disease progression in dysferlinopathy
Objective To assess the ability of functional measures to detect disease progression in dysferlinopathy over 6 months and 1 year. Methods One hundred ninety-three patients with dysferlinopathy were recruited to the Jain Foundation9s International Clinical Outcome Study for Dysferlinopathy. Baseline, 6-month, and 1-year assessments included adapted North Star Ambulatory Assessment (a-NSAA), Motor Function Measure (MFM-20), timed function tests, 6-minute walk test (6MWT), Brooke scale, Jebsen test, manual muscle testing, and hand-held dynamometry. Patients also completed the ACTIVLIM questionnaire. Change in each measure over 6 months and 1 year was calculated and compared between disease severity (ambulant [mild, moderate, or severe based on a-NSAA score] or nonambulant [unable to complete a 10-meter walk]) and clinical diagnosis. Results The functional a-NSAA test was the most sensitive to deterioration for ambulant patients overall. The a-NSAA score was the most sensitive test in the mild and moderate groups, while the 6MWT was most sensitive in the severe group. The 10-meter walk test was the only test showing significant change across all ambulant severity groups. In nonambulant patients, the MFM domain 3, wrist flexion strength, and pinch grip were most sensitive. Progression rates did not differ by clinical diagnosis. Power calculations determined that 46 moderately affected patients are required to determine clinical effectiveness for a hypothetical 1-year clinical trial based on the a-NSAA as a clinical endpoint. Conclusion Certain functional outcome measures can detect changes over 6 months and 1 year in dysferlinopathy and potentially be useful in monitoring progression in clinical trials. ClinicalTrials.gov identifier: NCT01676077.
- 1 October 2016
- Published by Elsevier in Neuromuscular Disorders
- Vol. 26, S186
Cross-sectional data on the 100 meter timed test in boys with Duchenne muscular dystrophy compared to age-matched controls
- 1 October 2016
- Published by Elsevier in Neuromuscular Disorders
- Vol. 26, S186
Cross-sectional data on the 100 meter timed test in boys with Duchenne muscular dystrophy compared to age-matched controls
- 1 October 2016
- Published by Elsevier in Neuromuscular Disorders
- Vol. 26, S102
Pilot data evaluating the utility of ACTIVE-mini as a biomarker in spinal muscular atrophy type 1
- 1 October 2016
- Published by Elsevier in Neuromuscular Disorders
- Vol. 26, S102
Pilot data evaluating the utility of ACTIVE-mini as a biomarker in spinal muscular atrophy type 1
- 1 October 2016
- Published by Elsevier in Neuromuscular Disorders
- Vol. 26, S187
Validation of ACTIVE with the PROMIS patient-reported measure of upper extremity function in males with Duchenne muscular dystrophy
- 1 October 2016
- Published by Elsevier in Neuromuscular Disorders
- Vol. 26, S187
Validation of ACTIVE with the PROMIS patient-reported measure of upper extremity function in males with Duchenne muscular dystrophy
- 1 October 2016
- Published by Elsevier in Neuromuscular Disorders
- Vol. 26, S186-S187
Evaluating the effect of a monetary incentive on performance of the 100-meter timed test in Duchenne muscular dystrophy
- 1 October 2016
- Published by Elsevier in Neuromuscular Disorders
- Vol. 26, S186-S187
Evaluating the effect of a monetary incentive on performance of the 100-meter timed test in Duchenne muscular dystrophy
- Open Access
- 1 May 2016
- Published by Elsevier in Molecular Therapy
- Vol. 24, S197-S198
497. Follistatin Gene Therapy Improves Six Minute Walk Distance in Sporadic Inclusion Body Myositis (sIBM)
- 1 May 2016
- Published by Elsevier in Molecular Therapy
- Vol. 24, S197-S198
Open Access497. Follistatin Gene Therapy Improves Six Minute Walk Distance in Sporadic Inclusion Body Myositis (sIBM)